CDC42 and neoplasm: Previous studies indicated that ketorolac increases ovarian‐,8 non–small‐cell lung‐,9 kidney‐ and breast cancer‐specific10 survival, which may be attributed to the ability of the R‐enantiomer to reduce tumour growth, invasion and metastasis via Rac1/Cdc42 inhibition.11